Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoogkamp-Korstanje, J A A
Right arrow Articles by Bruyn, G A W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoogkamp-Korstanje, J A A
Right arrow Articles by Bruyn, G A W
Ann Rheum Dis 2000;59:914-917 ( November )

Concise report

Ciprofloxacin v placebo for treatment of Yersinia enterocolitica triggered reactive arthritis J A A Hoogkamp-Korstanjea, H Moeskerb, G A W Bruync

a Department of Medical Microbiology, University Hospital Nijmegen, Geert Grooteplein 24, 6500 HB Nijmegen, The Netherlands, b Department of Clinical Development, Bayer BV, Energieweg 1, 3641 RT Mijdrecht, The Netherlands, c Department of Rheumatology, Medisch Centrum Leeuwarden, Henry Dunantweg 2, 8934 AD Leeuwarden, The Netherlands

Correspondence to: Dr Hoogkamp-Korstanje J.Hoogkamp{at}mmb.azn.nl

Accepted for publication 12 April 2000

Patients with yersinia triggered reactive arthritis were double blind randomly allocated to receive treatment with ciprofloxacin 500 mg twice daily orally or placebo during three months. The diagnosis was made by serology (specific IgA and IgG antibodies to yersinia outer membrane proteins (yops)), positive culture, and/or demonstration of Yersinia enterocolitica antigen in colon biopsy specimens. Patients were evaluated monthly during and after treatment up to 12 months. Of 18 patients enrolled, all could be evaluated for safety, 16 for efficacy. There was a tendency towards faster remission and relief of pain in those receiving ciprofloxacin. Y enterocolitica was eliminated from the gut associated lymphoid tissue in six of seven patients receiving ciprofloxacin compared with none of nine patients receiving placebo. Patients receiving placebo had more and prolonged circulating IgA antibodies against yops than patients treated with ciprofloxacin.

© 2000 by Annals of the Rheumatic Diseases


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
T K Kvien, J S H Gaston, T Bardin, I Butrimiene, B A C Dijkmans, M Leirisalo-Repo, P Solakov, M Altwegg, P Mowinckel, P-A Plan, et al.
Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study
Ann Rheum Dis, September 1, 2004; 63(9): 1113 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
T Yli-Kerttula, R Luukkainen, U Yli-Kerttula, T Mottonen, M Hakola, M Korpela, M Sanila, J Uksila, and A Toivanen
Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis
Ann Rheum Dis, September 1, 2003; 62(9): 880 - 884.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2000 BMJ Publishing Group Ltd & European League Against Rheumatism